Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Germ Cell and Embryonal × Genitourinary × Clear all
NCT02859415 2022-04-05

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 10 charts
GastrointestinalGenitourinaryOther solid neoplasmSarcomaThoracic

Esophageal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Germ Cell and Embryonal, Sarcoma, Thymus Neoplasms, Colorectal Neoplasms